Recent Company News

• 10:14 AM ET Nov 13, 2025
  

  Transcript Intelligence: Innate Pharma Q3 Sales and Revenue Guidance (€1.62, -0.04)

• 10:13 AM ET Nov 13, 2025
  

  Transcript Intelligence: Innate Pharma Q3 Sales and Revenue Q&A (€1.62, -0.04)

• 10:13 AM ET Nov 13, 2025
  

  Transcript Intelligence: Innate Pharma Q3 Sales and Revenue Themes (€1.62, -0.04)

• 01:09 AM ET Nov 13, 2025
  

  Innate Pharma reports 9-Months revenue €2.3M vs year-ago €10.2M (€1.66, 0.00)

• 03:27 PM ET Nov 12, 2025
  

  Transcript Intelligence: Innate Pharma at Stifel Healthcare Conference (€1.66, 0.00)

• 09:17 AM ET Nov 10, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 04:35 AM ET Nov 10, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:05 AM ET Nov 10, 2025
  

  Innate Pharma announces FDA clearance to proceed with TELLOMAK 3, a confirmatory Phase 3 trial of Lacutamab in CTCL (€1.52, 0.00)

• 04:17 PM ET Oct 29, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:50 AM ET Oct 29, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market